Industry Press Releases

NeuroVive Pharmaceutical AB (publ) - Amendment Number of Shares and Votes

Monday, Feb 29, 2016

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of share issue in kind conducted by NeuroVive Pharmaceutical AB (publ) (“NeuroVive”), as resolved by the Board of Directors on 13 January 2016 with the authorization by the annual general meeting on 30 March 2015, the number of shares and votes of NeuroVive registered with the Swedish Companies Registration Office have increased by 738,533. Accordingly, the total number of shares and votes in NeuroVive is 31,473,685.

About NeuroVive

NeuroVive Pharmaceutical AB (publ) is a pioneer in mitochondrial medicine and a company committed to the discovery and development of highly targeted candidates that preserve mitochondrial integrity and function in areas of significant therapeutic need. NeuroVive’s business approach is driven by value-adding partnerships with mitochondrial research institutions and commercial partners across the globe. NeuroVive’s portfolio consists of two clinical projects in acute kidney injury (AKI) and traumatic brain injury (TBI) with candidates in clinical and preclinical development and two drug discovery platforms. The NeuroSTAT® product has orphan drug status in Europe and in the US for treatment of moderate to severe traumatic brain injury and is currently being evaluated in a study, CHIC. Ciclosporin is being evaluated in an on-going study, CiPRICS, in acute kidney injury during major surgery. NeuroVive’s shares are listed on Nasdaq, Stockholm, Sweden.

NeuroVive Pharmaceutical AB (publ) is required to publish the information in this news release under The Swedish Securities Market Act. The information was submitted for publication on 29 February, 2016, at 8.30 a.m. CET.

NeuroVive Pharmaceutical AB (publ) - the mitochondrial medicine company. The company is listed on Nasdaq Stockholm, Small Cap, under the ticker symbol NVP. The share is also traded on the OTC market in the US. NeuroVive Pharmaceutical (OTC: NEVPF) trades on the OTC Pink Current. Investors can find Real-Time quotes and market information for the company at

This information was brought to you by Cision

NeuroVive Pharmaceutical AB
Investor Relations
Christine Tadgell
Tel: +46 (0)46 275 62 21
NeuroVive Pharmaceutical AB
Tel: +46 (0)46 275 62 20 (switchboard)
Fax: +46 (0)46 888 83 48


Source :

Other Press Releases